Skip to content

Merck HCV combination effective after failure of first generation of direct-acting antivirals

Dr Xavier Forns of Hospital Clinic, Barcelona, presents results of the C-SALVAGE study. Photo by Liz Highleyman, hivandhepatitis.com

HCV viral load levels during treatment and speed of decline do not predict cure with interferon-free therapy

David Wyles presenting at CROI 2015. Photo by Liz Highleyman, hivandhepatitis.com

Global hepatitis B epidemic treatable at cost of just $36 per patient per year

End-stage liver disease is a concern for people with HIV and hepatitis B or C co-infection

Cannabis use reduces risk of insulin resistance in people with HIV/HCV co-infection

HCV sexual transmission linked to anal sex, drug use, lower CD4 count

Sustained virological response represents a long-term cure for people with hepatitis C treated with sofosbuvir

Re-infection due to ongoing risk probably the cause of HCV recurrence after SVR

Sofosbuvir/ledipasvir raises some antiretroviral levels in HIV/HCV coinfected people